Editas Medicine

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.

We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Stock Symbol: EDIT

Stock Exchange: NASDAQ

11 Hurley Street
Cambridge, Massachusetts 02141 USA
AWARDS
  • NextGen Class of 2015
NEWS
The U.S. Patent and Trademark Office (USPTO) granted Emmanuelle Charpentier, co-founder of ERS Genomics, the University of California and University of Vienna, their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners.
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
A look at three small biotech companies that appear to be leading the CRISPR race.
A look at a biotech company that represents a solid trend in the industry.
It’s not always easy to see when a company is a “disruptor,” which is to say, that it causes a paradigm shift in how an industry operates.
The hearing will focus on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA.
JOBS
IN THE PRESS